The North America sepsis diagnostics market is expected to grow from US$ 279.06 million in 2021 to US$ 513.33 million by 2028. It is estimated to record a CAGR of 9.1% from 2021 to 2028.

High Incidence of Sepsis due to Increasing Nosocomial Infections Drives North America Sepsis Diagnostics Market

Sepsis, a life-threatening condition, is fundamentally caused by infection and disproportionately affects immunocompromised individuals. This includes patients undergoing chemotherapy, those who have had a splenectomy, and individuals battling conditions like AIDS and diabetes. Among various types of infections, nosocomial infections are a primary cause of illness and mortality in hospitalized patients. The Centers for Disease Control and Prevention (CDC)'s "2020 National and State Healthcare-Associated Infections Progress Report," published in 2021, revealed a significant rise in these infections in the US between 2019 and 2020: central line-associated bloodstream infections increased by approximately 24%, ventilator-associated events by 35%, and Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia by 15%.

According to the Global Sepsis Alliance (GSA), nearly 26 million people worldwide develop sepsis annually, resulting in around 8 million deaths. Many of these fatalities, often linked to diarrheal diseases or lower respiratory infections, are preventable through early diagnosis and appropriate clinical management. Consequently, the escalating incidence of bloodstream infections and the overall high rate of sepsis are expected to significantly boost the demand for sepsis diagnostic products, fueling growth in the North America sepsis diagnostics market during the forecast period.

Download our Sample PDF Report

@ https://www.businessmarketinsights.com/sample/BMIRE00025664

North America Sepsis Diagnostics Strategic Insights

North America Sepsis Diagnostics Strategic Insights offers a data-driven analysis of the industry landscape, encompassing current trends, key players, and distinct regional characteristics. These insights provide actionable recommendations, empowering readers to distinguish themselves from competitors by identifying untapped market segments or crafting unique value propositions. By leveraging data analytics, these insights help industry stakeholders—whether investors, manufacturers, or others—anticipate market shifts. A future-oriented perspective is essential, helping stakeholders foresee market changes and position themselves for sustained success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

North America Sepsis Diagnostics Market Segmentation

North America Sepsis Diagnostics Market By Product

Instruments

Reagents and Assays

Blood Culture Media

Software

North America Sepsis Diagnostics Market By Technology

Molecular Diagnostics

By Flow Cytometry, Microfluidics, Immunoassay, Biomarkers, Microbiology)

North America Sepsis Diagnostics Market By Method

Automated Diagnostics and Conventional Diagnostics

North America Sepsis Diagnostics Market By Test Type

Point-of-Care Tests and Laboratory Tests

North America Sepsis Diagnostics Market Regions and Countries Covered          

North America

US

Canada

Mexico

North America Sepsis Diagnostics Market  leaders and key company profiles     

Abbott

BD

bioMerieux SA

Danaher (Beckman Coulter)

F. HOFFMANN-LA ROCHE LTD.

Immunexpress Inc.

Luminex Corporation

T2 Biosystems, Inc.

THERMO FISHER SCIENTIFIC INC.

About Us:

Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications